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Connective Tissue Disease*
Kelly Chin, MD, MSCS,y Stephen C. Mathai, MD, MHSzI n this issue of the Journal, Kusunose et al. (1)describe the use of exercise testing as a meansof identifying connective tissue disease (CTD)
patients at high risk of developing pulmonary hyper-
tension (PH). Their most important ﬁnding was that
individuals with greater exercise-related increases
in mean pulmonary artery pressure relative to cardiac
output (DmPAP/DCO) were more likely to develop PH
during follow-up (1). This ﬁnding, if conﬁrmed in
larger studies, could lead to improved screening
methods for patients with CTD (primarily sclero-
derma) and potentially for other at-risk populations.
PH complicates many forms of CTD, but is most
commonly seen in scleroderma and is a leading cause
of death in this patient population (2,3). Annual
screening for PH is recommended in both patients
with scleroderma and those with mixed CTD with
scleroderma features (4). Echocardiography (at rest)
is the most common screening modality because it
allows estimation of pulmonary artery systolic pres-
sures as well as evaluation for any right heart
enlargement. Right heart catheterization (RHC) is
recommended when suspicious ﬁndings are seen
on echocardiogram, but a signiﬁcant number of
false negatives and false positives occur (5). Some-
what better screening accuracy can be achieved
by using echocardiography along with pulmonary
function testing, N-terminal pro-B-type natriuretic
peptide levels, and other clinical results, as shown
in the DETECT study; use of this algorithm has
been recommended for higher risk scleroderma
patients (4,5).*Editorials published in the Journal of the American College of Cardiology
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approach. First, a negative screen only provides
information about current PH risk and, despite a lack
of studies supporting this approach, annual testing is
generally recommended. Second, even with annual
screening, some patients will be diagnosed with PH at
an advanced stage, either because of a missed diag-
nosis during screening or rapid interval progression.
Finally, current screening does not provide insight
into future risk of PH, which is a signiﬁcant limitation
if trying to plan preventive therapy studies or to
narrow future screening to a more select group of
high-risk individuals.
Exercise testing is therefore an appealing alternative.
Exercise echocardiography was previously used as a
method to identify “exercise-associated PH,” formerly
deﬁned as an mPAP >30 mm Hg during exercise. Cur-
rent PH guidelines recommend against this deﬁnition
because some normal individuals will develop pulmo-
nary pressure elevations in this range, usually related to
achieving a cardiac output of >10 liters/min during
exercise or from exercise-related increases in left atrial
pressure (6). In addition, the clinical relevance of
exercise-associated PH using this deﬁnition has not
been demonstrated. Nevertheless, a growing amount of
literature in this area suggests that normal ranges as
well as patterns of disease can be deﬁned if the full
pressure-ﬂow relationship is accounted for.
In other words, measurement of pulmonary artery
systolic pressure or mPAP at exercise alone, without
knowledge of the CO achieved, is much less infor-
mative than assessment of both mPAP and CO (7,8).
Because the normal pulmonary vascular response to
exercise-associated increases in CO is vasodilation
and vessel recruitment, PAP increases only modestly
and pulmonary vascular resistance typically falls
during exercise in healthy individuals (7). In contrast,
a steeper increase in mPAP will be seen for any given
rise in CO in individuals with pulmonary vascular
disease (Figure 1) (9–11).
FIGURE 1 Linear Pressure Flow (mPAP/CO) Relationship on
the Basis of Averages of Serial Measurements During
Incremental Exercise
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386In the current study, Kusunose et al. (1) evaluate
whether exercise testing using a combination of
echocardiography and electric biometry can predict
future PH in high-risk patients with CTD. Consistent
with their hypothesis, post-6-min walking distance
mPAP, mPAP/Q, and DmPAP/DQ were all predictors of
future PH in their univariate analysis (1). They also
found that DmPAP/DQ (the only post-exercise hemo-
dynamic measure tested) was a predictor of future PH
in their multivariate model (1).Slope = 2.2 Slope = 0.8
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Includes normal young adults (Reeves), patients with sclero-
derma without PH and with borderline PH (Kovacs), and patients
with resting PH (Janicki). Adapted from Lewis (11). Reprinted
with permission of Advances in Pulmonary Hypertension.
CO ¼ cardiac output; mPAP ¼ mean pulmonary artery pressure;
PH ¼ pulmonary arterial hypertension.
SEE PAGE 376Strengths of their study include the use of RHC for
diagnosing PH and the use of a longitudinal rather
than a cross-sectional design. Prior cross-sectional
studies have found steeper increases in PAP during
exercise in various forms of PH (12,13) as well as in
patients with conditions associated with PH, such
as scleroderma, congestive heart failure, chronic
obstructive pulmonary disease, and even in family
members of PH patients (10,14–16). However, long-
term follow-up has not previously been performed.
The current study’s combination of noninvasive
screening plus comprehensive long-term follow-up
provides a “proof-of-concept” look at the potential role
for exercise testing in screening for PH in scleroderma.
There are several limitations to the current study.
Noninvasive estimates of PAP and CO can vary
signiﬁcantly from values obtained at RHC, particu-
larly with exercise (7,17), and the investigators do not
directly compare their noninvasive measures of
pressure and ﬂow during exercise with invasively
measured parameters. Furthermore, rapid declines in
PAP and CO occur immediately following exercise
cessation; thus, the chosen method may fail to iden-
tify patients with high mPAP/CO relationships at peak
exercise and lead to misclassiﬁcation (8). RHC was
also only performed in individuals with a mPAP
estimate $25 mm Hg on echocardiography; therefore,
the sensitivity and speciﬁcity of their screening
measure cannot be determined—although the rela-
tively long follow-up (median 32 months) lessens the
likelihood that PH was missed. The absence of eval-
uation for elevated left atrial pressure during exercise
is also a limitation of the technique, as one would
anticipate that heart failure with preserved ejection
fraction would not be rare in PH in CTD (although notreported in this study) and that this would contribute
to exercise-associated increases in mPAP (14,18).
Finally, although physiological principles suggest
that post-exercise mPAP alone would not be as
effective as DmPAP/DQ, mPAP at peak exercise was a
strong predictor of future PH in this cohort in the
univariate evaluation, and evidence that DmPAP/DQ
performed better than post-exercise mPAP would
have signiﬁcantly strengthened the study.
In summary, Kusunose et al. (1) report the novel
ﬁnding that CTD patients with greater increases in
pulmonary arterial pressures relative to cardiac
output are at increased risk of developing PH during
long-term follow-up. The study rationale makes sense
from a physiological standpoint, but requires conﬁr-
mation in larger multicenter studies.
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